Sutent Shows Promise in Helping Advanced Pancreatic Cancer Patients

by: cancercompass

Patients with advanced pancreatic cancer saw increased progression-free survival when prescribed Sutent over a placebo, reports Pfizer of its phase III clinical trial of the cancer drug.

Reuters reports 154 patients with advanced pancreatic islet cell tumors participated in the study, which was stopped early because it reached its primary trial goal. Overall, it took five months longer for the disease to worsen in patients taking Sutent than for those prescribed a placebo.

Patients receiving Sutent experienced the following side effects: low white blood cells, high blood pressure, abdominal pain, diarrhea, low blood sugar and swelling of the hands and feet.  Pfizer told Reuters these side effects are consistent with previous Sutent studies.

Researchers continue to analyze the data.

What are doctors prescribing for your pancreatic cancer? Discuss your treatments and experiences with other cancer patients and survivors at our Pancreatic Cancer Message Board.